ClinicalTrials.gg
Not yet recruitingNCT07458113BERLINUpdated Jul 24, 2026

Sac-TMT for Active TNBC Brain Metastases

A Phase 2 interventional study of Sacituzumab tirumotecan in Metastatic Triple Negative Breast Cancers, sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms — 9 open to participants now, 11 under way, 5 of them phase 3. sacituzumab tirumotecan · Triple Negative Breast Neoplasms.

Planned enrollment
12th of 12
20 · median 152
Started
2026
the only one that year
Phase 2
6 of 12
5 open now
Primary completion
2028-08
later than 7 of 10 live
Registered
12th of 12
by date
Lead sponsor
1 of 12
Yale University

Among the 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 12th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

9 of the 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About sacituzumab tirumotecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacceptable toxicities, consent withdrawal, or death.

03

Conditions studied

  • Metastatic Triple Negative Breast Cancers

Keywords

  • Sacituzumab tirumotecan
  • metastatic TNBC
  • brain metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Individuals of all races and ethnic groups are eligible for this trial. There is no bias towards age, sex or race in the clinical trial outlined. This trial is open to the accrual of men and women.

Inclusion criteria

Inclusion Criteria:

  1. An individual of any sex/gender who is at least 18 years of age at the time of providing the .
  2. Individuals who are unable to provide informed consent may be included if a Legally Authorized Representative (LAR) is available and able to provide consent on their behalf.
  3. and/or cytologically confirmed triple-negative breast cancer defined by estrogen receptor (ER) expression \<10%, progesterone receptor expression \<10% and -negative status, defined by 0, 1+ or 2+ FISH negative by immunohistochemistry (IHC) by standard pathology.
  4. Newly diagnosed untreated or brain metastases progressing after prior local therapy (including surgery and/or radiation therapy).
  5. Intracranial (RANO-BM criteria).

    1. Measurable disease is defined as a contrast enhancing lesion that is at least 10 mm in longest diameter, visible on two or more axial slices, and at least 5 mm in diameter perpendicular to the longest diameter. Non-measurable disease includes lesions that are less than 10 mm, those with borders that are not able to be reproducibly measured, dural metastases, bony metastases, , and cystic-only lesions.
    2. Note, presence of measurable or non-measurable disease as per 1.1 assessed by the treating investigator/radiologist not required for eligibility.
  6. There is no clinical indication for immediate local treatment with surgery or radiation therapy by the treating investigator's assessment.
  7. Absence of documented leptomeningeal disease (LMD) by cytology. Note: clinical findings or neuroimaging indicating suspected LMD are allowed, so long as cerebrospinal fluid (CSF) cytology is negative.
  8. Performance Status (ECOG-PS) 0-1.
  9. No restriction on the number of lines of prior systemic or local anticancer therapies

    1. Prior therapy must include treatment with an antibody-drug conjugate either per standard of care or as an drug.
  10. of at least three months (12 weeks) per treating investigator's assessment.
  11. Adequate treatment before C1D1, as outlined below:

    Major Surgery: minimum washout period of greater than or equal to 4 weeks Therapeutic or palliative stereotactic radiation therapy systemically or to CNS: minimum washout period of greater than or equal to 4 weeks Anticancer systemic therapy with : no washout period Anticancer system therapy including cytotoxic chemotherapy, and antibody-based therapy: minimum washout period of greater than or equal to 3 weeks Targeted agents and small molecules: minimum washout period of greater than or equal to 2 weeks or five half-lives, whichever is longer Strong cytochrome P450 () inducers/inhibitors: minimum washout period of greater than or equal to 2 weeks Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated ): minimum washout period of greater than 30 days. Note: Participants, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of study intervention.

  12. If available, a mandatory agreement to provide an sample or most recently obtained core, incisional, or excisional biopsy of a tumor lesion from any site. Fresh tissue collection is not required. There are no tissue biomarker requirements for study participation beyond the IHC subtype as described in the inclusion criteria.
  13. Adequate organ function as defined below. Specimens must be collected within 72 hours before the start of the study intervention.

    greater than equal to 1500 per microliter of blood count greater than or equal to 100,000 per microliter of blood count greater than or equal to 9.0 g/dL or greater than or equal to 5.6 mmol/L Measured or calculated creatine clearance greater than or equal to 30 mL/min Total count less than or equal to 1.5 x or direct bilirubin ≤ULN for participants with total bilirubin levels. >1.5 × ULN (Serum Glutamic-Oxaloacetic Transaminase) and alanine aminotransferase(Serum Glutamate-Pyruvate Transaminase) count less than or equal to 2.5 x ULN (less than or equal to 5 x ULN for participants with liver metastases) or prothrombin time/partial thromboplastin time less than or equal to 1.5 x ULN

  14. Be willing and able to comply with study procedures, laboratory tests, and other requirements of the study.
  15. -infected participants must have well-controlled HIV on antiretroviral therapy (ART), defined as:

    1. Having a greater than or equal to 350 cells/mm3 at the time of screening.
    2. Having achieved and maintained virologic suppression, defined as confirmed HIV RNA level below 50 or the LLOQ using the locally available assay, at the time of registration and for at least 12 weeks before registration.
    3. Absence of any AIDS-defining opportunistic infections within the past 12 months.
    4. Being on a stable regimen, without changes in drugs or dose modification, for at least four weeks before registration and agreeing to continue ART throughout the study.

    Note: The ART regimen must not contain any antiretroviral medications that are strong CYP3A4 inducers/inhibitors/substrates. The treating investigator should review the locally approved label for all concomitant therapy to ensure it is not a strong inducer/inhibitor/substrate of CYP3A4.

    e. HIV testing at screening is not required unless: i. There is a known history of HIV infection. ii. Mandated by local guidelines.

  16. Participants who are positive are eligible if they have received HBV antiviral therapy for at least four weeks or have undetectable HBV viral load before registration.

    Note: Participants who are under treatment for HBV should remain on antiviral therapy throughout the study intervention and follow local guidelines for HBV antiviral therapy post-completion of the study intervention.

    1. Hepatitis B testing at screening is not required unless:

    i. There is a known history of HBV infection. ii. Mandated by local guidelines.

  17. Participants with a history of infection are eligible if the HCV viral load is undetectable at screening.

    a. Hepatitis C testing at screening is not required unless: i. There is a known history of HCV infection. ii. Mandated by local guidelines.

  18. Participants must adhere to the following reproductive and requirements while on study treatment and for 210 days after the last dose of the study drug:

    a. General Requirements: i. Participants must not be pregnant or breastfeeding. ii. Participants must not donate gametes (i.e., eggs or sperm) or freeze gametes for future use related to assisted reproduction.

    b. For participants of (POCBP): i. Participant of childbearing potential is defined as an individual who is premenopausal and capable of becoming pregnant, including those using contraception, those who are single, or those with partners who have had a vasectomy.

ii. A negative serum pregnancy test must be obtained at screening within 72 hours before the first dose of the study treatment, and participants must agree to further pregnancy tests throughout the study, if required.

iii. Participants must practice at least one highly effective method of contraception.

c. For Partners of Participants: i. If the participant's partner is of childbearing potential, the partner must also practice a highly effective method of contraception while the participant is on study treatment and for 120 days after the last dose of the study drug, unless the participant is vasectomized.

d. Highly effective methods of contraception include: i. Combined hormonal contraception (estrogen and progestogen) that inhibits ovulation (oral, intravaginal, or transdermal).

ii. Progestogen-only hormonal contraception that inhibits ovulation (oral, injectable, or implantable).

iii. Intrauterine device (IUD). iv. Intrauterine hormone-releasing system. v. Bilateral tubal occlusion. vi. Sexual abstinence (the reliability of abstinence must be evaluated concerning the duration of the clinical study and the participant's lifestyle).

vii. A vasectomized partner (provided the partner is the sole sexual partner of the POCBP study participant and that the vasectomized partner has received medical confirmation of the surgical success).

Exclusion criteria

Exclusion Criteria:

  1. Prior use of sacituzumab tirumotecan.
  2. Known to sacituzumab tirumotecan or any of the drug components
  3. Other concomitant anticancer therapy, including cytotoxic, targeted agents, immunotherapy, antibody, retinoid, or anti-cancer hormonal treatment with the exception of osteoprotective therapies such as denosumab or bisphosphonates.

    Note: Radiotherapy to CNS is allowed during the study if intracranial disease progresses clinically or radiologically without extracranial disease progression, with drug being held prior to radiation and a of three weeks follows the end of radiation prior to resuming therapy.

  4. A history of uncontrolled seizures (more than two seizures within 28 days prior to registration), CNS disorders, or psychiatric disability judged by the treating investigator to be and adversely affecting compliance with study drug.
  5. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  6. Pregnant or lactating women.
  7. Participants requiring concomitant use of chronic systemic (IV or oral) at doses higher than 8 mg dexamethasone per day or other medications except for managing adverse events; inhaled steroids or intra articular steroid injections are permitted in this study.
  8. Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
  9. Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of (Fridericia's formula) interval to >480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months before the first dose of study intervention.
  10. Is currently enrolled in the active treatment phase of another therapeutic clinical trial.
  11. Has a known additional that is systemically progressing.
  12. Has an active infection requiring systemic therapy.
  13. Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the individual's ability to cooperate with the requirements of the study, or interfere with the individual's participation for the full duration of the study, such that it is not in the best interest of the individual to participate, in the opinion of the treating investigator.
  14. Has had major surgery or significant traumatic injury within four weeks before the first dose of study intervention.

    Note: Participants who underwent major surgery must have adequately recovered from toxicity and/or complications from the surgery before starting the study intervention.

  15. Has current Grade >2 pneumonitis/interstitial lung disease.
  16. Received a live or within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
  17. Is currently receiving a strong inducer/inhibitor of that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sacituzumab tirumotecan

    Sacituzumab tirumotecan will be administered by IV infusion on days 1, and 15 of each 28-day cycle. The duration of the sacituzumab tirumotecan infusions should be 90 minutes (±15 minutes), and infusion-related AEs will be monitored.

    Drug: Sacituzumab tirumotecan

Interventions

  • Sacituzumab tirumotecan should begin within three days of registration. For all study interventions administered based on weight, the participant's weight at screening or at cycle 1, day 1 should be used to calculate the initial dose. The participant's weight will be determined before each dose of sacituzumab tirumotecan. If, at any time throughout the course of treatment, the participant's weight changes by ≥10% from baseline, the dose will be recalculated using this new weight and will be considered the new baseline for all subsequent dosing calculations. The dose(s) of study intervention(s) should be recalculated as needed throughout the study. Dose adjustments for changes in body weight \<10% are permitted per institutional standards. Sacituzumab tirumotecan will be administered by IV infusion on days 1, and 15 of each 28-day cycle. The duration of the sacituzumab tirumotecan infusions should be 90 minutes (±15 minutes), and infusion-related AEs will be monitored.

06

What researchers measure

Primary outcomes

  1. Intracranial response rate determined by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) in patients with metastatic triple-negative breast cancer and brain metastases.

    To determine the intracranial efficacy of sacituzumab tirumotecan in patients with metastatic triple-negative breast cancer and brain metastases. RANO-BM evaluates treatment response by categorizing results into Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)

    Time frame: At screening and every 8 weeks during the treatment period (up to one year)

Secondary outcomes

  1. Intracranial clinical benefit rate by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) in patients with metastatic triple-negative breast cancer and brain metastases.

    To determine the intracranial and extracranial efficacy of sacituzumab tirumotecan in patients with metastatic triple-negative breast cancer and brain metastases. RANO-BM evaluates treatment response by categorizing results into Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD).

    Time frame: At baseline and every 8 weeks during the treatment period (up to 1 year)

  2. Extracranial objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in patients with metastatic triple-negative breast cancer and brain metastases

    To determine the intracranial and extracranial efficacy of sacituzumab tirumotecan in patients with metastatic triple-negative breast cancer and brain metastases. The RECIST 1.1 scale assesses cancer treatment response in clinical trials. It defines four response categories-Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD)-based on the sum of the longest diameters of target lesions.

    Time frame: At baseline and every 8 weeks during the treatment period (up to 1 year)

  3. Extracranial clinical benefit rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients with metastatic triple-negative breast cancer and brain metastases

    To determine the intracranial and extracranial efficacy of sacituzumab tirumotecan in patients with metastatic triple-negative breast cancer and brain metastases. The RECIST 1.1 scale assesses cancer treatment response in clinical trials. It defines four response categories-Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD)-based on the sum of the longest diameters of target lesions.

    Time frame: At baseline and every 8 weeks during the treatment period (up to 2 years)

  4. Intracranial progression-free survival in patients with metastatic triple-negative breast cancer and brain metastases

    To determine the survival benefit of sacituzumab tirumotecan in patients with metastatic triple-negative breast cancer and brain metastases.

    Time frame: Every 12 weeks during the survival follow up phase (until death or lost to follow up. Participants will be followed for up to 1 year after completing or stopping protocol treatment)

  5. Overall survival rate in patients with metastatic triple-negative breast cancer and brain metastases

    To determine the survival benefit of sacituzumab tirumotecan in patients with metastatic triple-negative breast cancer and brain metastases.

    Time frame: One year post-treatment

  6. Adverse events recorded in patients with metastatic triple-negative breast cancer and brain metastases

    Adverse events, as classified by Common Terminology Criteria for Adverse Events (CTCAE 5.0), will be monitored and recorded to determine the safety of sacituzumab tirumotecan in treating patients with metastatic triple-negative breast cancer and brain metastases.

    Time frame: At day 1 and day 15 of each cycle, where each cycle is 28 days. At the end of treatment visit (1 year after cycle 1 day 1 OR upon discontinuation of treatment) and at the safety follow-up visit that occurs 30 days after the last dose

  7. Serious adverse events recorded in patients with metastatic triple-negative breast cancer and brain metastases

    Serious adverse events, as classified by Common Terminology Criteria for Adverse Events (CTCAE 5.0), will be monitored and recorded to determine the safety of sacituzumab tirumotecan in treating patients with metastatic triple-negative breast cancer and brain metastases.

    Time frame: At day 1 and day 15 of each cycle, where each cycle is 28 days. At the end of treatment visit (1 year after cycle 1 day 1 OR upon discontinuation of treatment) and at the safety follow-up visit that occurs 30 days after the last dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 24 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Mar 9, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2029
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07458113
Lead sponsor
Yale University
Collaborators
Johns Hopkins University, Merck Sharp & Dohme LLC, Translational Breast Cancer Research Consortium
Responsible party
Adriana Kahn (Assistant Professor, Yale University) — Principal investigator
First posted
Mar 9, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Jul 24, 2026

Study contacts

Laura Kane
Contact
laura.kane@yale.edu
773-369-6904
Adriana Kahn, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion